Information Provided By:
Fly News Breaks for March 9, 2015
OREX
Mar 9, 2015 | 06:59 EDT
Piper Jaffray believes the data reported by Orexigen last week gives the company an additional seven years of intellectual property protection and an "implicit marketing advantage." The firm thinks the "noise" around the implications with partner Takeda and the FDA from the data release will not compromise the company from a regulatory or reputational standpoint. Piper reiterates an Overweight rating on Orexigen with a $26 price target.
News For OREX From the Last 2 Days
There are no results for your query OREX
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.